Education
About Us
Working with TipRanks
Follow Us
Ocugen Inc (OCGN)
:OCGN
OCGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.52 - $1.90
Previous CloseN/A
Volume1.89M
Average Volume (3M)5.27M
Market Cap
$552.78M
Enterprise Value$289.23M
Total Cash (Recent Filing)$27.01M
Total Debt (Recent Filing)$32.82M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Nov 07, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding312,304,750
10 Day Avg. Volume8,851,280
30 Day Avg. Volume5,269,531
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue60.84
Enterprise Value/Gross Profit60.84
Enterprise Value/Ebitda-5.53
Forecast
1Y Price Target
$8.50Price Target Upside380.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Partnership AgreementsA binding term sheet was signed for commercialization rights to OCU400 in retinitis pigmentosa for the Republic of Korea, with quite favorable terms.
Pipeline DevelopmentOcugen remains focused on advancing its modifier gene therapy pipeline for ophthalmology, including OCU400 in retinitis pigmentosa, which is on track to complete its pivotal in 2025 and to file for its BLA in 2026, which is considered to be the near-term value driver.
Regulatory AdvancementsOCU400 in retinitis pigmentosa has received RMAT and orphan drug designation from the FDA, potentially allowing for priority review and faster market entry.
Bears Say
Clinical HoldIn April 2023, the FDA placed OCU200's IND for a P1 targeting diabetic macular edema on clinical hold.
Financial PerformanceOcugen reported 2Q25 results with a net loss of ($14.7M) and a cash position of $27.0M.
Project TerminationThe previously planned merger agreement, effectively a spinout transaction for Ocugen, with Ocugen's Orthcellix subsidiary was terminated due to failure to secure the required funding.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.52 and its highest was $1.90 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $552.78M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Nov 07, 2025 which is in 32 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Aug 01, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.056 by $0.006.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.06.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 312,304,750 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.056. Following the earnings report the stock price went down -3.883%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (380.23% Upside)
$8.50 (380.23% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 70%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
86.90%
12-Months-Change
Fundamentals
Return on Equity
-569.99%
Trailing 12-Months
Asset Growth
32.19%
Trailing 12-Months
Company Description
Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
OCGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical development and strategic partnerships, including FDA and EMA approvals, and successful clinical trial data. However, there are concerns about declining cash reserves and operating expenses.View all OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$8.50
▲(380.23% Upside)
Technical Analysis
Ownership Overview
1.68% Insiders
7.74% Mutual Funds
2.72% Other Institutional Investors
83.68% Public Companies and Individual Investors